Dr. Michael J. Lazar

Avatar

About Dr. Michael J. Lazar

Michael J. Lazar, M.D. graduated from the University of Arkansas in 1978 and completed postgraduate training in surgery and urology at LSU in 1983. He is four-time board certified by the American Board of Urology and is Managing Physician Director of Santa Rosa Surgical Management Co., LLC, which manages Santa Rosa Memorial Hospital’s Ambulatory Surgery Center. He is also Chairman of the Board of Directors of Redwood Health Services and is a member of the American Urological Association. Dr. Lazar is married with 3 children, and has been active in Boy Scout leadership and coaching soccer. His hobbies include hiking, backpacking, camping, alpine skiing, and the occasional fly-fishing outing. Dr. Lazar also enjoys living in the wine country, which affords cultivation of a love of wine, and proximity to San Francisco allows enjoyment of its theater and fine arts. Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU, a medical procedure that applies high-intensity focused ultrasound energy to locally heat and destroy diseased or damaged tissue with prostate cancer through ablation. Dr. Lazar is working closely with SonaCare to bring this innovative service to Americans with this disease.

Compounds in coffee may inhibit the growth of prostate cancer

For the first time, scientists have identified compounds found in coffee which may inhibit the growth of prostate cancer. This is a pilot study, carried out on drug-resistant cancer cells in cell culture and in a mouse model; it has not yet been tested in humans. This work is presented at the European Association of Urology congress in Barcelona, after publication in the peer-reviewed journal The Prostate. Coffee is a complex mixture of compounds which has been shown to influence human health in both positive and negative ways. There is increasing evidence that drinking certain types of coffee is associated with a reduction in incidence of some cancers, including prostate cancers. Now Japanese scientists have studied the effects of two compounds found in coffee, [...]

2019-03-19T08:36:47-07:00March 19th, 2019|

Who is the best candidate for HIFU prostate cancer treatment?

Is HIFU Prostate Cancer Treatment for You? High Intensity Focused Ultrasound (HIFU) is a FDA approved non-invasive therapy for treating prostate cancer. Find out if you qualify for HIFU. HIFU may not be appropriate in every situation, but it is most effective for men who have early stage, localized prostate cancer that has not spread or metastasized outside the prostate. HIFU is an FDA approved precise and targeted therapy that reduces the risk of complications caused by surgery and radiation. HIFU uses ultrasound energy, or sound waves, to heat and destroy specifically targeted areas of tissue. During HIFU, the sound waves pass through healthy tissue without causing damage. At the focal point of the sound waves (like a magnifying glass focusing the rays of [...]

2019-03-12T08:42:04-07:00March 12th, 2019|

No obvious benefits for prostate cancer patients using low-dose aspirin

Low-dose aspirin use does not seem to reduce the overall risk for prostate cancer death at the population level. However, results for extended exposure periods suggest that low-dose aspirin might be inversely associated with prostate cancer mortality after 5 years from cancer diagnosis. Findings from a nationwide cohort study are published in Annals of Internal Medicine. Recent studies suggest that aspirin use may improve survival in patients with prostate cancer, but study results are inconclusive. Researchers from the Danish Cancer Society Research Center, Aarhus University Hospital, Copenhagen University Hospital, and University of Southern Denmark used nationwide registries in Denmark to assess the association between postdiagnosis use of low-dose aspirin and prostate cancer mortality. Their analysis did not find convincing evidence of an overall protective [...]

2019-03-05T11:54:54-07:00March 5th, 2019|

HIFU Patients Urged to Advocate for Reimbursements

Advocating for HIFU Reimbursement Men who may have benefited from HIFU for Prostate Cancer are being asked to help more men receive this life-saving procedure. HIFU Prostate Services and California HIFU is asking past-patients to help newly diagnosed men have a greater opportunity to receive HIFU for prostate cancer by advocating for higher Medicare reimbursement for HIFU. The steps have been outlined below to help with this process, along with tips for being as effective as possible. Finding Your Representatives Click here to search the House of Representatives Click here to search for your Senators Write a Letter to Your Representatives in Congress Now that you have found your representatives in Congress and the Senate, one of the easiest ways to help is to [...]

2019-02-26T08:19:47-07:00February 26th, 2019|

Active surveillance nearly tripled in men with low-risk prostate disease

Many men with low-risk prostate cancer who most likely previously would have undergone immediate surgery or radiation are now adopting a more conservative "active surveillance" strategy, according to an analysis of a new federal database by scientists from Dana-Farber Cancer Institute. The use of active surveillance increased from 14.5 percent to 42.1 percent of men with low-risk prostate cancer between 2010 and 2015, said the researchers, led by Brandon Mahal, MD, from the department of radiation oncology at Dana-Farber/Brigham and Women's Cancer Center who led the study published by JAMA. During that same period, the percentage of men undergoing radical prostatectomy (removal of the prostate gland) declined from 47.4 percent to 31.3 percent. The use of radiotherapy for low-risk disease dropped from 38.0 percent [...]

2019-02-12T11:42:12-07:00February 12th, 2019|

HIFU: Creating A New Prostate Cancer Treatment Paradigm

Utilizing focused ultrasound, the Sonablate system is a minimally invasive robotic device that delivers precise and focused ablative energy. This new surgical option for prostate cancer gives surgeons minimally invasive options for destroying unhealthy tissue with thermal ablation throughout the body. This is a new treatment paradigm that combines elements from radiology, needle ablation and surgery to effectively ablate targeted tissue with minimal impact on a patient's quality of life. Reduced side effect profiles Reduced procedure time Tissue sparing intervention across specialties More favorable outcomes via "non-cutting" intervention. Imaging and feedback tools provide live results from targeted area(s) Increases the number of patients appropriate for surgical intervention Reduces costs associated with surgical intervention Minimally Invasive Real-time Imaging Radiation Free Don't wait until it's too late. [...]

2019-02-05T08:55:07-07:00February 5th, 2019|

Prostate Cancer News: PSA screening significantly reduces the risk for death

After differences in implementation and settings were accounted for, two important prostate cancer screening trials provide compatible evidence that screening reduces prostate cancer mortality. After differences in implementation and settings were accounted for, two important prostate cancer screening trials provide compatible evidence that screening reduces prostate cancer mortality. These findings suggest that current guidelines recommending against routine PSA-based screening may be revised. However, questions remain about how to implement screening so that the benefits outweigh the potential harms of over-diagnosis and overtreatment. The findings are published in Annals of Internal Medicine. Current guidelines from the United States Preventive Services Task Force (USPSTF) recommend against prostate-specific antigen (PSA) screening for prostate cancer because the evidence for the test showed very low probability that it would [...]

2019-01-16T09:41:10-07:00January 16th, 2019|

Fewer men are being screened, diagnosed, and treated for prostate cancer

A new study reveals declines in prostate cancer screening and diagnoses in the United States in recent years, as well as decreases in the use of definitive treatments in men who have been diagnosed. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. There is considerable debate surrounding the value of prostate cancer screening with prostate-specific antigen (PSA) testing, and the 2012 United States Preventive Services Task Force (USPSTF) recommendation against PSA testing lies at the center of this debate. This recommendation was made in part due to the potential harms -- such as erectile dysfunction and urinary incontinence -- associated with the treatment of clinically insignificant prostate cancer with radical prostatectomy or radiation. To examine the [...]

2019-01-15T11:04:18-07:00January 15th, 2019|

Study finds needle biopsy procedure may miss higher-risk cancer

Genetic alterations in low-risk prostate cancer diagnosed by needle biopsy can identify men that harbor higher-risk cancer in their prostate glands, Mayo Clinic has discovered. The research, which is published in the January edition of Mayo Clinic Proceedings, found for the first time that genetic alterations associated with intermediate- and high-risk prostate cancer also may be present in some cases of low-risk prostate cancers. The study found the needle biopsy procedure may miss higher-risk cancer that increases the risk of disease progression. Researchers say that men diagnosed with low-risk cancer may benefit from additional testing for these chromosomal alterations. "We have discovered new molecular markers that can help guide men in their decisions about the course of their prostate cancer care," says George Vasmatzis, [...]

2019-01-08T11:03:52-07:00January 8th, 2019|

Excess body weight contributes to aggressive prostate cancer risk

Researchers look at differences between states with the highest and lowest proportions of cancers attributable to excess body weight A new study looking at the share of cancers related to obesity finds an at least 1.5-fold difference between states with the highest and lowest proportions. The proportion of cancer cases that could be attributable to excess body weight ranged from a high of 8.3% in the District of Columbia to a low of 5.9% in Hawaii, reflecting variations in obesity rates in the states. The study appears in JAMA Oncology. Excess body weight is an established cause of cancer, currently known to be linked to 13 cancers. While differences in excess body weight among states in the United States are well-known, there is little [...]

2019-01-02T10:35:55-07:00January 2nd, 2019|